ALB and cancer: <h4>Objective</h4>To evaluate the clinical efficacy and safety of toripalimab combined with albumin-bound paclitaxel and cisplatin/carboplatin as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC).<h4>Methods</h4>Thirty-five patients with advanced R/MHNSCC admitted to Hunan Cancer Hospital (January 2021-December 2023) received first-line treatment with toripalimab plus albumin-bound paclitaxel and cisplatin/carboplatin.